![AstraZeneca Exec Discusses Iressa's Future in the U.S.](https://cdn.cancerletter.com/media/2015/08/24044804/41-31Andrew-Coop.jpg)
![AstraZeneca Exec Discusses Iressa's Future in the U.S.](https://cdn.cancerletter.com/media/2015/08/24044804/41-31Andrew-Coop.jpg)
Cover Story
Conversation with The Cancer LetterFree
After a decade of near-absence from the US market, the AstraZeneca drug Iressa (gefitinib) is back.
In Brief
![In Brief](https://cdn.cancerletter.com/media/2019/05/03155624/in-brief-3.jpg)
![In Brief](https://cdn.cancerletter.com/media/2019/05/03155624/in-brief-3.jpg)
Drugs & Targets
Trending Stories
- How Beth Carner went from six weeks left to live with stage 4 colon cancer to complete remission
- Infections are a major cause of death in patients treated with CAR T-cell therapy
Meta-analysis focused on causes of death, excluding relapse, recurrence - Robert Gallo named founding director of Microbial Oncology Program at TGH Cancer Institute
- In 1971, Chris Lundy had minute odds of survival. He is now the longest living BMT recipient at the Hutch
- What are you reading in 2023?
- Lei Zheng named executive director of Mays Cancer Center